首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   62584篇
  免费   6772篇
  国内免费   1733篇
耳鼻咽喉   517篇
儿科学   1175篇
妇产科学   375篇
基础医学   4340篇
口腔科学   6151篇
临床医学   8684篇
内科学   14453篇
皮肤病学   862篇
神经病学   2214篇
特种医学   1078篇
外国民族医学   1篇
外科学   5089篇
综合类   10191篇
现状与发展   13篇
一般理论   3篇
预防医学   4088篇
眼科学   522篇
药学   5254篇
  65篇
中国医学   4676篇
肿瘤学   1338篇
  2024年   198篇
  2023年   1434篇
  2022年   2043篇
  2021年   3502篇
  2020年   3238篇
  2019年   2662篇
  2018年   2482篇
  2017年   2768篇
  2016年   2990篇
  2015年   2958篇
  2014年   4409篇
  2013年   4886篇
  2012年   3816篇
  2011年   4155篇
  2010年   3067篇
  2009年   2870篇
  2008年   2610篇
  2007年   2760篇
  2006年   2477篇
  2005年   2185篇
  2004年   1880篇
  2003年   1735篇
  2002年   1293篇
  2001年   1144篇
  2000年   926篇
  1999年   734篇
  1998年   608篇
  1997年   605篇
  1996年   566篇
  1995年   539篇
  1994年   491篇
  1993年   396篇
  1992年   376篇
  1991年   296篇
  1990年   227篇
  1989年   220篇
  1988年   185篇
  1987年   162篇
  1986年   166篇
  1985年   205篇
  1984年   150篇
  1983年   109篇
  1982年   122篇
  1981年   130篇
  1980年   74篇
  1979年   52篇
  1978年   54篇
  1977年   42篇
  1976年   38篇
  1975年   17篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
71.

Background

Chronic limb-threatening ischemia (CLTI), defined as ischemic rest pain or tissue loss secondary to arterial insufficiency, is caused by multilevel arterial disease with frequent, severe infrageniculate disease. The rise in CLTI is in part the result of increasing worldwide prevalence of diabetes, renal insufficiency, and advanced aging of the population. The aim of this study was to compare a bypass-first with an endovascular-first revascularization strategy in patients with CLTI due to infrageniculate arterial disease.

Methods

We reviewed the American College of Surgeons National Surgical Quality Improvement Program targeted lower extremity revascularization database from 2012 to 2015 to identify patients with CLTI and isolated infrageniculate arterial disease who underwent primary infrageniculate bypass or endovascular intervention. We excluded patients with a history of ipsilateral revascularization and proximal interventions. The end points were major adverse limb event (MALE), major adverse cardiovascular event (MACE), amputation at 30 days, reintervention, patency, and mortality. Multivariable logistic regression was used to determine the association of a bypass-first or an endovascular-first intervention with outcomes.

Results

There were 1355 CLTI patients undergoing first-time revascularization to the infrageniculate arteries (821 endovascular-first revascularizations and 534 bypass-first revascularizations) identified. There was no significant difference in adjusted rate of 30-day MALE in the bypass-first vs endovascular-first revascularization cohort (9% vs 11.2%; odds ratio [OR], 0.73; 95% confidence interval [CI], 0.50-1.08). However, the incidence of transtibial or proximal amputation was lower in the bypass-first cohort (4.3% vs 7.4%; OR, 0.60; CI, 0.36-0.98). Patients with bypass-first revascularization had higher wound complication rates (9.7% vs 3.7%; OR, 2.75; CI, 1.71-4.42) compared with patients in the endovascular-first cohort. Compared with the endovascular-first cohort, the incidence of 30-day MACE was significantly higher in bypass-first patients (6.9% vs 2.6%; adjusted OR, 3.88; CI, 2.18-6.88), and 30-day mortality rates were 3.23% vs 1.8% (adjusted OR, 2.77; CI, 1.26-6.11). There was no difference in 30-day untreated loss of patency, reintervention of treated arterial segment, readmissions, and reoperations between the two cohorts. In subgroup analysis after exclusion of dialysis patients, there was also no significant difference in MALE or amputation between the bypass-first and endovascular-first cohorts.

Conclusions

CLTI patients with isolated infrageniculate arterial disease treated by a bypass-first approach have a significantly lower 30-day amputation. However, this benefit was not observed when dialysis patients were excluded. The bypass-first cohort had a higher incidence of MACE compared with an endovascular-first strategy. These results reaffirm the need for randomized controlled trials, such as the Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL-2) trial and Best Endovascular vs Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI), to provide level 1 evidence for the role of endovascular-first vs bypass-first revascularization strategies in the treatment of this population of challenging patients.  相似文献   
72.
73.
74.
75.
Spinal cord stimulation (SCS) is widely used for pain relief in patients with failed back surgery syndrome (FBSS), and muscle weakness is a common finding in patients with chronic pain. We present here a single case report of a 47‐year‐old woman, who, after SCS for FBSS, had continuous improvement in lower leg muscle strength and gait, but only transient and minimal pain relief. To the authors’ knowledge, this is only the second published case report of significant improvement in “motor” function, independent of the analgesic effect following SCS in FBSS. If SCS, in fact, does improve muscle strength, new strategies for the management of patients with chronic pain might be opened up. Further studies are needed to verify this hypothesis.  相似文献   
76.
目的 观察不同钙离子浓度的透析液对血液透析患者透析后血清钙离子水平及血压变化的影响,为肾功能衰竭血液透析患者的高钙血症及高血压的防治提供依据。方法 选择不同钙离子浓度的透析液,将维持性血液透析患者分为高钙组(1.75mmol/L)和低钙组(1.25mmol/L),比较患者每次透析前后脉搏、血压,同时抽查患者透析前后血钙及血肌酐浓度的变化。结果透析后两组患者血肌酐浓度均显著下降,透析前后差异均具有统计学意义(P〈0.01);高钙组患者透析后血钙较透析前升高,差异具有统计学意义(P〈0.01),而低钙组患者血钙比透析前略降低,差异无统计学意义(P〉0.05)。高钙组患者透析后较透析前收缩压、舒张压及平均动脉压都升高,差异均具有统计学意义(P〈0.05),而低钙组患者透析后较透析前收缩压、舒张压及平均动脉压都降低,差异均具有统计学意义(P〈0.05)。透析后两组血钙比较差异具有统计学意义(P〈0.01);透析后低钙组较高钙组患者的收缩压、舒张压及平均动脉压都降低,三者差异均具有统计学意义(P〈0.01)。结论透析液钙离子浓度与血液透析患者血清钙离子水平及血压呈正相关,低钙透析液透析有助于维持性血液透析患者高血压的控制。  相似文献   
77.
生物羊膜覆盖治疗早期重度眼表烧伤   总被引:1,自引:1,他引:0  
周霞  许玲  孙斌 《眼科新进展》2006,26(11):860-861
目的探讨生物羊膜在早期重度眼表烧伤中的临床疗效。方法对17例(20眼)重度眼表烧伤患者施行生物羊膜覆盖术。随访3~7月,观察临床疗效。结果术后全部患者均保存了眼球。角膜恢复透明11眼,角膜斑翳7眼,角膜白斑2眼,角膜新生血管9眼,睑球粘连1眼。12眼视力提高>3行。无急性排斥反应和继发感染发生。结论生物羊膜覆盖是治疗早期重度眼表烧伤一种安全有效的方法。  相似文献   
78.
凯时治疗慢性重型肝炎患者疗效观察   总被引:2,自引:0,他引:2  
目的探讨凯时即前列地尔脂微球载体制剂(Lipo-PGE1)治疗慢性重型肝炎的疗效。方法将84例慢性重型肝炎患者随机分成两组,对照组予综合治疗及对症治疗,治疗组在该基础上加用凯时10μg溶于5%葡萄糖注射液250ml中静脉缓慢滴注,1次/d,疗程为4周。结果治疗组对慢性重型肝炎的疗效优于对照组(P〈0.01),肝功能改善优于对照组(P〈0.01)。结论Lipo-PCEI是一种治疗慢性重型肝炎安全、有效的药物。  相似文献   
79.
80.
目的探讨重症急性胰腺炎的合理治疗方案。方法以1985年1月~2005年8月间收治的102例重症急性胰腺炎作研究对象,比较手术组与非手术组的主要并发症和死亡率。A组:1985年1月~1993年12月以手术治疗为主41例;B组:1994年1月~2005年8月以早期非手术治疗为主61例。结果手术组死亡率和并发症发生率明显高于非手术组,两组病死率及并发症发生率比较差异有显著性(P〈0.05)。结论重症急性胰腺炎采用早期非手术治疗能有效降低病死率和并发症发生率。大多数重症急性胰腺炎可经非手术治愈。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号